{
    "organizations": [],
    "uuid": "9c1b87e393745e43084bda2b59095194d716a0a7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-akcea-and-ionis-complete-licensing/brief-akcea-and-ionis-complete-licensing-transaction-to-commercialize-inotersen-idUSFWN1RU0YN",
    "ord_in_thread": 0,
    "title": "BRIEF-Akcea And Ionis Complete Licensing Transaction To Commercialize Inotersen",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Akcea Therapeutics Inc:\n* AKCEA AND IONIS COMPLETE LICENSING TRANSACTION TO COMMERCIALIZE INOTERSEN FOR HATTR\n* AKCEA THERAPEUTICS - CO & IONIS PLAN TO COMMENCE CLINICAL STUDIES FOR AKCEA-TTR-L(R) IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T21:08:00.000+03:00",
    "crawled": "2018-04-18T18:11:14.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "akcea",
        "therapeutic",
        "inc",
        "akcea",
        "ionis",
        "complete",
        "licensing",
        "transaction",
        "commercialize",
        "inotersen",
        "hattr",
        "akcea",
        "therapeutic",
        "co",
        "ionis",
        "plan",
        "commence",
        "clinical",
        "study",
        "r",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}